Related Experiment Video

Updated: May 14, 2026

In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

Health innovation in cardiovascular diseases

Su May Liew1, Adina Abdullah, Nurdiana Abdullah

  • 1Department of Primary Care Medicine, University of Malaya Primary Care Research Group (UMPCRG), Faculty of Medicine, University of Malaya, Kuala Lumpur.

The Australasian Medical Journal
|February 21, 2013
PubMed

Insights

Novel health innovations can revolutionize cardiovascular disease (CVD) management. Exploring new technologies and knowledge is crucial for addressing the escalating global burden of CVD.

Area of Science:

  • Cardiology
  • Health Innovation
  • Public Health

Background:

  • Cardiovascular disease (CVD) is the primary cause of global mortality and morbidity.
  • The prevalence of CVD is increasing worldwide, necessitating novel solutions.
  • Existing management strategies require enhancement through innovation.

Purpose of the Study:

  • To explore novel health innovations for cardiovascular disease (CVD) management.
  • To identify areas where new knowledge and technology can revolutionize CVD care.
  • To highlight opportunities for innovation in CVD prevention and treatment.

Main Methods:

  • Review of published studies on cardiovascular disease (CVD).
  • Identification of emerging innovations in global risk assessment, monitoring, and testing.
  • Exploration of pharmacogenetics and lifestyle change support as innovation areas.

Main Results:

  • Innovations generated in global risk assessment, home and remote monitoring, and bedside testing.
  • Pharmacogenetics and lifestyle support methods identified as key innovation topics.
  • Gaps in current CVD knowledge and practice offer opportunities for new developments.

Conclusions:

  • Health innovations hold significant potential to transform cardiovascular disease (CVD) management.
  • New technologies and approaches are vital to combat the rising CVD epidemic.
  • Healthcare professionals must understand innovation limitations and prioritize patient well-being.

Keywords:
Health innovationscardiovascular diseases

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However, frequent irregular...
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...